Tempus AI, Inc. - Class A Common Stock (TEM)

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.

Polovin's sale of 30,075 shares was non-discretionary and tied to tax withholding from RSU vesting.

Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.

This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.

These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.

This sale was non-discretionary, executed to cover tax withholding from RSU vesting.

This filing details a non-discretionary sale that reduced Lefkofsky's direct holdings by a small percentage.

Tempus AI Inc. (NASDAQ: TEM) stock jumped on Friday, August 7, 2026, following strong AI healthcare peer earnings from Doximity Inc. and a strategic lab expansion with CellCarta.

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve

Tempus AI Inc. (NASDAQ: TEM) shares are trading lower Friday as traders digest post-earnings reset in expectations.

Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.

AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a potentially powerful growth engine.

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou

Tempus AI is growing fast, but the real debate is whether its healthcare data platform can justify the premium price investors are already paying.

Tempus AI (NASDAQ: TEM) stock is surging Thursday after launching a first-of-its-kind open-source digital pathology consortium with Yale New Haven Health and MSK.

This technology-driven firm delivers software and insurance solutions for home services professionals, homebuyers, and homeowners.

Discover why Tempus AI Inc (NASDAQ:TEM) stock is surging today following major platform expansions and landmark clinical data ahead of ASCO 2026.

The widely followed growth investor keeps making moves.

The old healthcare model is breaking down.

Tempus AI (TEM) Q1 2026 Earnings Transcript

The convergence of two already fantastic industries is creating an incredible opportunity.

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets like gold, but there’s increased evidence that this rotation is expanding to include many blue-chip stocks. For example, The Coca-Cola Co. (NYSE: KO) stock is up more than 10% in February.